D. Egan

发表

A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine

S. Dorman, M. Hatherill, P. Denti, 2019, Antimicrobial Agents and Chemotherapy.

Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.

T. Harrer, J. van Lunzen, M. Vogel, 2008, The Journal of antimicrobial chemotherapy.

Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals

M. Youle, M. Johnson, J. Rockstroh, 2011, The Journal of antimicrobial chemotherapy.

Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population

M. Youle, S. Khoo, C. Smith, 2009, HIV medicine.

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms

S. Khoo, Chloe E. James, A. Owen, 2010, Pharmacogenetics and genomics.

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

D. Cooper, P. Phanuphak, S. Khoo, 2015, Clinical Pharmacokinetics.

Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir.

S. Khoo, D. Back, H. Reynolds, 2015, The Journal of antimicrobial chemotherapy.

Cytotoxic chemotherapy and the evolution of cellular and viral resistance to antiretroviral therapy in HIV- infected individuals with lymphoma

A. Owen, N. Liptrott, M. Boffito, 2016, HIV clinical trials.

The Relationships of ABCB1 3435C>T and CYP2B6 516G>T With High‐Density Lipoprotein Cholesterol in HIV‐Infected Patients Receiving Efavirenz

M. Youle, S. Khoo, C. Smith, 2009, Clinical pharmacology and therapeutics.

Plasma and Intracellular (Peripheral Blood Mononuclear Cells) Pharmacokinetics of Once-Daily Raltegravir (800 Milligrams) in HIV-Infected Patients

B. Clotet, N. Liptrott, D. Back, 2010, Antimicrobial Agents and Chemotherapy.

Estimation of the Effect of Slco1B1 Polymorphisms on Lopinavir Plasma Concentration in HIV-Infected Adults

M. Youle, S. Khoo, A. Owen, 2012, Antiviral therapy.

Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis

A. Owen, S. Naiker, S. Hennig, 2015, Antimicrobial Agents and Chemotherapy.

Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.

T. Harrer, A. Jetter, A. Owen, 2011, The Journal of antimicrobial chemotherapy.

CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults.

S. Khoo, A. Owen, D. Back, 2014, Pharmacogenetics & Genomics.

A Compartmental Pharmacokinetic Evaluation of Long‐Acting Rilpivirine in HIV‐Negative Volunteers for Pre‐Exposure Prophylaxis

B. Gazzard, B. Herold, M. Boffito, 2014, Clinical pharmacology and therapeutics.

Polymorphisms of tenofovir disoproxil fumarate transporters and risk of kidney tubular dysfunction in HIV-positive patients: genetics of tenofovir transporters

S. Khoo, F. Post, M. Danjuma, 2018, International journal of STD & AIDS.

Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk.

L. Myer, S. Khoo, C. Orrell, 2018, Bioanalysis.

Quantification of rilpivirine in human plasma, cervicovaginal fluid, rectal fluid and genital/rectal mucosal tissues using liquid chromatography-tandem mass spectrometry.

S. Khoo, M. Boffito, D. Back, 2014, Bioanalysis.

Pharmacokinetic and Pharmacodynamic Comparison of Once‐Daily Efavirenz (400 mg vs. 600 mg) in Treatment‐Naïve HIV‐Infected Patients: Results of the ENCORE1 Study

D. Cooper, P. Phanuphak, S. Khoo, 2015, Clinical pharmacology and therapeutics.

The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma.

S. Khoo, M. Boffito, D. Back, 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.

S. Khoo, F. Sarfo, A. Owen, 2014, The Journal of antimicrobial chemotherapy.

Estimation of the effect of SLCO 1 B 1 polymorphisms on lopinavir plasma concentration in HIV-infected adults

M. Youle, A. Owen, M. Boffito, 2012 .

Antigen Presentation by an Immature Myeloid Dendritic Cell Line Does Not Cause CTL Deletion In Vivo, but Generates CD8+ Central Memory-Like T Cells That Can Be Rescued for Full Effector Function1

R. Offringa, C. Melief, H. Dumortier, 2005, The Journal of Immunology.

Rescued for Full Effector Function Central Memory-Like T Cells That Can Be + CTL Deletion In Vivo, but Generates CD8 Myeloid Dendritic Cell Line Does Not Cause Antigen Presentation by an Immature

R. Offringa, C. Melief, H. Dumortier, 2005 .

The SLCO1B1 rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications

S. Pushpakom, G. Maartens, P. Denti, 2011, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP)

S. Khoo, C. Herrera, J. Fox, 2021, The Journal of antimicrobial chemotherapy.

Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study.

V. Soriano, S. Khoo, A. Owen, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

IFN-&ggr; 874A>T Genotype Is Associated With Higher CCR5 Expression in Peripheral Blood Mononuclear Cells From HIV+ Patients

A. Owen, N. Liptrott, D. Back, 2011, Journal of acquired immune deficiency syndromes.

Widespread use of herbal medicines by people living with human immunodeficiency virus and contamination of herbal medicines with antiretrovirals in Nigeria

S. Khoo, D. Back, J. Chiong, 2018, International journal of STD & AIDS.

Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis

S. Khoo, A. Owen, S. Ward, 2017, Antimicrobial Agents and Chemotherapy.

Arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of Rifapentine: a population pharmacokinetics analysis.

S. Dorman, M. Hatherill, P. Denti, 2019 .

Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis

S. Khoo, C. Herrera, J. Fox, 2016, Journal of acquired immune deficiency syndromes.

The SLCO1B1 rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications

S. Pushpakom, G. Maartens, P. Denti, 2011, Antimicrobial Agents and Chemotherapy.

Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population

M. Youle, C. Smith, T. Mahungu, 2009, HIV medicine.

AUTOSTERE: Systematic Search for Scaffold Replacement Opportunities within Structural Databases

Joseph M. Sheridan, Saye Khoo, Jonathan R. Heal, 2021, J. Chem. Inf. Model..

CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults.

S. Khoo, A. Owen, D. Back, 2014, Pharmacogenetics and genomics.